Trials / Active Not Recruiting
Active Not RecruitingNCT02401685
POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer
POSNOC - POsitive Sentinel NOde: Adjuvant Therapy Alone Versus Adjuvant Therapy Plus Clearance or Axillary Radiotherapy. A Randomised Controlled Trial of Axillary Treatment in Women With Early Stage Breast Cancer Who Have Metastases in One or Two Sentinel Nodes
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,900 (actual)
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
POSNOC is a pragmatic, randomised, multicentre, non-inferiority trial. Aim For women with early stage breast cancer and one or two sentinel node macrometastases, to assess whether adjuvant therapy alone is no worse than adjuvant therapy plus axillary treatment, in terms of axillary recurrence within 5 years. Stratification: Institution, Age (\<50, ≥50), Breast-conserving surgery (BCS) or mastectomy, Estrogen receptor (ER) status (positive, negative), Number of positive nodes (1, 2), Intra-operative sentinel assessment using OSNA (yes, no). Interventions The study will compare adjuvant therapy alone with adjuvant therapy plus axillary treatment (axillary node clearance (ANC) or axillary radiotherapy (ART)). Sample Size: 1900 participants Follow-up: Participants will be followed up for 5 years. Adjuvant Therapy: All participants will receive adjuvant systemic therapy (chemotherapy and/or endocrine therapy). All participants may receive breast/chest wall radiotherapy. Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to adjuvant therapy alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Adjuvant therapy | Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated. |
| PROCEDURE | Axillary treatment | Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines. |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2026-07-01
- Completion
- 2026-12-31
- First posted
- 2015-03-30
- Last updated
- 2025-07-10
Locations
50 sites across 3 countries: Australia, New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT02401685. Inclusion in this directory is not an endorsement.